Founder and CSO at Genomate Health
Dr Petak is a physician-scientist and entrepreneur involved in the evolution of precision oncology over the past thirty years. His journey started in 1995 in pediatric oncology, signal transduction therapy research, and molecular pharmacology at Semmelweis University and St. Jude Children’s Research Hospital.
In 2003, he was among the first to develop companion diagnostics for EGFR TKI and applied NGS in precision oncology in 2008. His work and vision on integrating molecular diagnostics in drug discovery were summarized in a 2010 publication in Nature Reviews Drug Discovery. In the following decade, he served on the molecular tumor board of over 10k cases. This led to his research on developing the right computational solution for precision oncology, called Digital Drug Assignment (DDA), which was published first in 2021. Dr. Petak has authored over 200 scientific papers and has multiple affiliations as a research professor at academic institutions.
Dr. Petak has co-founded three medical technology companies: KPS Biotechnology, founded in 2003, focused on the first single-gene biomarkers. Oncompass Medicine, founded in 2012, developed the first multigene diagnostic tests, and Genomate Health, founded in 2022, now focuses on computational solutions in precision oncology. Dr Petak and his companies have received multiple innovation awards, including the Breakthrough Innovation in Oncology Award of the American Society of Clinical Oncology, the Future Unicorn Award of DIGITALEUROPE, and Dr. Petak has also received the Denes Gabor Award for his pioneering work in medicine.
